Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–182 of 182 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Benign Prostatic Hypertrophy (BPH) Clear all
Not yet recruiting No phase listed Observational

The FLOW Registry.

NCT07430423
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 14, 2026, 6:22 AM EDT
Completed Not applicable Interventional Results available

UroLift System TOlerability and ReCovery When Administering Local Anesthesia

NCT01876706
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift® System
Device
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
San Diego, California • Daytona Beach, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 14, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

NCT00743184
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Interventions
ozarelix, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
50 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 14, 2026, 6:22 AM EDT
Recruiting Not applicable Interventional

Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

NCT06312722
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Optilume® BPH Catheter System
Device
Lead sponsor
Urotronic Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
7
States / cities
Little Rock, Arkansas • Tampa, Florida • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 14, 2026, 6:22 AM EDT
Active, not recruiting Not applicable Interventional

Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath

NCT05400980
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Urocross implant, Sham-control
Device · Diagnostic Test
Lead sponsor
Prodeon Medical, Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Maywood, Illinois • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 6:22 AM EDT
Withdrawn No phase listed Observational

RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-up

NCT05784558
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift System, Watchful Waiting or BPH Medications, Other Surgical Intervention
Device · Other
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
45 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 14, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS

NCT01589263
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Interventions
onaBoNT-A + placebo, Tamsulosin + placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 14, 2026, 6:22 AM EDT
Recruiting No phase listed Observational

Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry

NCT07538622
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia)
Interventions
Zenflow Spring System
Device
Lead sponsor
Zenflow, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Phoenix, Arizona • La Mesa, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 14, 2026, 6:22 AM EDT
Completed Phase 4 Interventional Results available

Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)

NCT05082142
View directory record Official record
Conditions
Kidney Calculi, Urologic Diseases, Benign Prostatic Hypertrophy
Interventions
Tranexamic acid
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 14, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional Results available

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

NCT03297398
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004), Placebo
Drug · Other
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
15
States / cities
Anniston, Alabama • Lincoln, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 14, 2026, 6:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Medical Therapy of Prostatic Symptoms

NCT00021814
View directory record Official record
Conditions
Prostatic Hyperplasia, Prostatic Hypertrophy, Benign
Interventions
Doxazosin, Finasteride, Doxazosin placebo, Finasteride placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
3,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2001
U.S. locations
17
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 14, 2026, 6:22 AM EDT
Completed Phase 3 Interventional

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

NCT01002222
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions
MCS-2
Drug
Lead sponsor
Health Ever Bio-Tech Co., Ltd.
Industry
Eligibility
40 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Oct 14, 2026, 6:22 AM EDT
Completed Phase 3 Interventional

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

NCT01846793
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
Interventions
NX-1207
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Laguna Beach, California • San Diego, California • Aventura, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 14, 2026, 6:22 AM EDT
Not yet recruiting Not applicable Interventional

Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia

NCT07772232
View directory record Official record
Conditions
Benign Prostate Hypertrophy(BPH), Lower Urinary Track Symptoms
Interventions
Device - HoLEP with MOSES 2.0, RWJA with Hydros Robotic System
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 14, 2026, 6:22 AM EDT